München, Germany

Helge Menzel


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 58(Granted Patents)


Location History:

  • Munchen, DE (1999)
  • München, DE (2001)

Company Filing History:


Years Active: 1999-2001

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Helge Menzel: Innovator in Tumor Cell Destruction

Introduction

Helge Menzel is a notable inventor based in München, Germany. He has made significant contributions to the field of medical technology, particularly in the area of stem cell transplants. With a total of two patents to his name, Menzel's work focuses on innovative methods for improving patient outcomes in cancer treatment.

Latest Patents

Menzel's latest patents include a groundbreaking procedure for the destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies. This invention discloses a method for effectively eliminating these harmful cells ex vivo, thereby enhancing the safety and efficacy of stem cell transplants. His work in this area represents a significant advancement in cancer therapy.

Career Highlights

Helge Menzel is associated with the GSF-Forschungszentrum für Umwelt und Gesundheit GmbH, where he has been instrumental in research and development. His expertise in the field has led to innovative solutions that address critical challenges in medical science.

Collaborations

Menzel has collaborated with esteemed colleagues such as Horst Lindhofer and Hans-Jochem Kolb. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their research.

Conclusion

Helge Menzel's contributions to the field of tumor cell destruction in stem cell transplants highlight his innovative spirit and dedication to improving medical treatments. His patents reflect a commitment to advancing healthcare and providing better solutions for patients facing cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…